Suppr超能文献

上海大规模单剂接种人群暴发疫情中水痘疫苗的有效性。

Effectiveness of varicella vaccination during an outbreak in a large one-dose-vaccinated population in Shanghai.

机构信息

Department of Immunology, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.

出版信息

Hum Vaccin Immunother. 2022 Dec 30;18(7):2143176. doi: 10.1080/21645515.2022.2143176. Epub 2022 Dec 12.

Abstract

Emergency vaccination (EV) is used as effective postexposure prophylaxis (PEP) to control varicella outbreaks within 3-5 days. However, the advantages of a second dose of varicella vaccine (VarV) in students who had received one dose before an outbreak and the potential benefits of EV at more than 5 days after exposure have not been fully evaluated. This study evaluated the vaccine effectiveness (VE) of EV in preventing disease development during a varicella outbreak in Shanghai, China, in 2020. Questionnaires were used to obtain student demographic information, clinical manifestations, varicella history, vaccination status, and willingness to receive EV. The VE of EV was calculated as [1-relative risk (RR)] ×100%. Among the 1455 students included in this study, 31 cases were identified, resulting in an overall attack rate of 2.13%. There were 6 cases in unvaccinated students and 25 cases in one-dose-vaccinated students. A total of 788 students received one EV dose. The attack rates were 6.38% (6/94), 4.26% (19/446), 2.82% (2/71), and 0.56% (4/717) among unvaccinated students, students who received 1 dose of VarV, and students who received EV with the 1 and 2 dose of VarV, respectively. Compared to that in unvaccinated students, the VE of EV with the 2 dose of VarV was 88% (95% CI 49% to 97%). EV should be performed as soon as possible after exposure. Nevertheless, vaccination is still recommended at more than 5 days post exposure to control varicella outbreaks.

摘要

应急接种(EV)被用作有效的暴露后预防(PEP)措施,可在 3-5 天内控制水痘暴发。然而,对于在暴发前已接种过一剂水痘疫苗(VarV)的学生,第二剂 VarV 的优势以及在暴露后超过 5 天进行 EV 的潜在益处尚未得到充分评估。本研究评估了 2020 年中国上海水痘暴发期间 EV 预防疾病发展的疫苗有效性(VE)。问卷调查用于获取学生的人口统计学信息、临床表现、水痘史、疫苗接种状况以及接受 EV 的意愿。EV 的 VE 计算为 [1-相对风险(RR)]×100%。在本研究纳入的 1455 名学生中,共发现 31 例病例,总发病率为 2.13%。未接种疫苗的学生中有 6 例,接种过一剂疫苗的学生中有 25 例。共有 788 名学生接受了一剂 EV。未接种疫苗的学生、接种过一剂 VarV 的学生、接种了一剂 VarV 加一剂 EV 的学生和接种了两剂 VarV 加一剂 EV 的学生的发病率分别为 6.38%(6/94)、4.26%(19/446)、2.82%(2/71)和 0.56%(4/717)。与未接种疫苗的学生相比,接种两剂 VarV 的 EV 的 VE 为 88%(95%CI 49%至 97%)。EV 应在暴露后尽快进行。然而,在暴露后超过 5 天仍建议进行接种,以控制水痘暴发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2436/9766464/2df53be1a9f5/KHVI_A_2143176_F0001_OC.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验